Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
Denali Therapeutics (DNLI) Stock Price & Analysis
597 Followers
DNLI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.56 - $29.22
Previous Close$21.46
Volume627.40K
Average Volume (3M)1.20M
Market Cap
$3.06B
Enterprise Value$2.07B
Total Cash (Recent Filing)$1.03B
Total Debt (Recent Filing)$44.98M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Aug 06, 2024EPS Estimate
-$0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding142,609,036
10 Day Avg. Volume1,615,868
30 Day Avg. Volume1,203,425
Standard Deviation0.18
R-Squared0.17
Alpha-0.00239
Financial Highlights & Ratios
Price to Book (P/B)3.13
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.29
Enterprise Value/Gross Profit6.27
Enterprise Value/Ebitda7.74
Forecast
1Y Price Target
$41.00Price Target Upside91.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Denali Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DataDNL310 achieves CSF HS normalization in 100% of patients.
Company's Financial HealthThe company has a strong cash position of $1.43B, which should adequately support all ongoing pipeline programs.
Regulatory ProgressDNL126 was selected by the FDA to be among the three therapies to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program.
Bears Say
Biology RiskAny program with such a novel mechanism faces considerable biology risk.
Regulatory ChallengesDenali Therapeutics could be required to submit longer-term clinical data for DNL310, which may delay potential accelerated approval until 2026.
Regulatory ChallengesThe FDA's request to convene an advisory committee for LLY's donanemab could delay its approval timeline, indicating regulatory challenges.
---
Ownership Overview
38.97% Insiders
28.86% Mutual Funds
15.15% Other Institutional Investors
17.02% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $14.56 and its highest was $29.22 in the past 12 months.
What is Denali Therapeutics’s market cap?
Currently, no data Available
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 15 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on May 07, 2024. The company reported -$0.68 earnings per share for the quarter, beating the consensus estimate of -$0.695 by $0.015.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -$0.67.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 142,609,040 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.68 in its last earnings report, beating expectations of -$0.695. Following the earnings report the stock price went up 12.166%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Among the largest hedge funds holding Denali Therapeutics’s share is Baker Bros Advisors LP. It holds Denali Therapeutics’s shares valued at 77M.
---
Denali Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.00 (91.05% Upside)
$41.00 (91.05% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 899.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.86%
12-Months-Change
Fundamentals
Return on Equity
-11.33%
Trailing 12-Months
Asset Growth
12.19%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
---
DNLI Stock 12 Month Forecast
Average Price Target
$41.00
▲(91.05% Upside)
Technical Analysis
Best Analysts Covering DNLI
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+46.37%
reiterated a buy rating 5 months ago
Copying Salveen Richter's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +46.37% per trade.
---